0001493152-23-016502.txt : 20230512 0001493152-23-016502.hdr.sgml : 20230512 20230512080926 ACCESSION NUMBER: 0001493152-23-016502 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20230508 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230512 DATE AS OF CHANGE: 20230512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Biofrontera Inc. CENTRAL INDEX KEY: 0001858685 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473765675 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40943 FILM NUMBER: 23913249 BUSINESS ADDRESS: STREET 1: 120 PRESIDENTIAL WAY, STREET 2: SUITE 330 CITY: WOBURN STATE: MA ZIP: 01801 BUSINESS PHONE: 781-245-1325 MAIL ADDRESS: STREET 1: 120 PRESIDENTIAL WAY, STREET 2: SUITE 330 CITY: WOBURN STATE: MA ZIP: 01801 8-K 1 form8-k.htm
0001858685 false 0001858685 2023-05-08 2023-05-08 0001858685 BFRI:CommonStockParValue0.001PerShareMember 2023-05-08 2023-05-08 0001858685 BFRI:PreferredStockPurchaseRightsMember 2023-05-08 2023-05-08 0001858685 BFRI:WarrantsEachWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf5.00PerShareMember 2023-05-08 2023-05-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): May 8, 2023

 

Biofrontera Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40943   47-3765675

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

120 Presidential Way, Suite 330

Woburn, Massachusetts

   01801
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (781) 245-1325

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, par value $0.001 per share   BFRI   The Nasdaq Stock Market LLC
         
Preferred Stock Purchase Rights       The Nasdaq Stock Market LLC
         
Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $5.00 per share   BFRIW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (the “Exchange Act”) (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
   

 

Item 2.02 Results of Operations and Financial Condition.

 

On May 12, 2023, Biofrontera Inc. (the “Company”) issued a press release announcing its financial and operational results for the first quarter ended March 31, 2023. A copy of the press release is being furnished as Exhibit 99.1 attached hereto to this Current Report on Form 8-K.

 

The Company’s press release contains non-GAAP financial measures. Generally, a non-GAAP financial measure is a numerical measure of a company’s performance, financial position, or cash flows that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with United States generally accepted accounting principles, or GAAP. Pursuant to the requirements of Regulation G, the Company has provided within the press release quantitative reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures.

 

The information contained in this Item 2.02 in the Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

On May 8, 2023, Erica Monaco, Chief Executive Officer of the Company notified the Company’s Board of Directors that she intends to resign from the Company to pursue other opportunities. The Company and Ms. Monaco have agreed to discuss an appropriate transition period, including the effective date of her resignation.

 

Item 7.01 Regulation FD Disclosure

 

On May 12, 2023, the Company issued a press release announcing Ms. Monaco’s resignation, a copy of which is attached here as Exhibit 99.2.

 

The information in Item 7.01 of this Current Report is being furnished and shall not be deemed “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

 

Item 9.01 Financial Statements and Exhibits.

 

99.1   Press release dated May 12, 2023 relating to the Company’s results for the quarter ended March 31, 2023
99.2   Press release dated May 12, 2023 relating to Ms. Monaco’s resignation
104   Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

 

 
   

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

May 12, 2023 Biofrontera Inc.
(Date) (Registrant)
   
  /s/ E. Fred Leffler
  E. Fred Leffler, III
  Chief Financial Officer

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

Biofrontera Inc. Reports First Quarter 2023 Financial Results and Provides a Business Update

 

Conference call begins at 8:30 a.m. Eastern time today

 

WOBURN, Mass. (May 12, 2023) – Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for the three months ended March 31, 2023 and provided a business update.

 

Highlights from the first quarter of 2023 and subsequent weeks included the following:

 

  ● Total revenues for the first quarter of 2023 were $8.7 million with both January and February at record-high monthly sales volumes
  ● Cash and cash equivalents were $13.5 million as of March 31, 2023, compared with $17.2 million on December 31, 2022
  ● Equity investment in shares of Biofrontera AG were $7.6 million as of March 31, 2023
  ● Entered into secured line of credit with borrowing up to $6.5 million
  ● Significantly strengthened the commercial team including adding a new sales region and increasing the size of the salesforce by nearly 30%, now covering 40 territories
  ● Announced first patient dosed in a pivotal Phase 3 clinical study evaluating Ameluz®-PDT for the treatment of actinic keratosis (AK) on the extremities, neck and trunk
  ● Announced last patient out in a Phase 1 clinical study evaluating the safety and tolerability of treating AK using three tubes of Ameluz®

 

Management Commentary

 

“Our sales team kicked off the year by producing record-high results in January and February, while quarterly sales growth is against a prior-year comparison that included considerable buy-in ahead of the April 2022 price increase. In fact, Ameluz tube volumes for the first quarter of 2023 exceeded any other first quarter that was not aided by a pending price increase, by at least 30%,” said Fred Leffler, Chief Financial Officer of Biofrontera Inc. “These metrics reflect the effective integration and mobilization of our recently bolstered sales force and give us confidence in affirming our full-year revenue expectations.”

 

“As we continue gaining market share for Ameluz-PDT, we look to a number of upcoming milestones from ongoing clinical trials to further expand the FDA label for Ameluz. These 2023 catalysts include reporting topline results from a three-tube study and completing enrollment in the Phase 3 extremities, neck and trunk clinical study and the Phase 3 basal cell carcinoma study,” he added.

 

 

 

 

First Quarter Financial Results

 

Total revenues for the first quarter of 2023 were $8.7 million compared with $9.8 million for the first quarter of 2022. The decrease is due to customer buy-in during the first quarter of 2022 prior to a planned price increase on April 1, 2022. The Company did not increase the price of Ameluz in 2023, and therefore did not see a similar buy-in effect from customers. First quarter 2023 revenues were 30% higher than any prior first quarter that did not benefit from a price increase.

 

Total operating expenses were $14.2 million for the first quarter of 2023 compared with $12.9 million for the first quarter of 2022. Cost of revenues was $4.6 million for the first quarter of 2023 compared with $5.2 million for the prior-year quarter, with the decline driven by lower Ameluz product revenue. Selling, general and administrative expenses were $9.8 million for the first quarter of 2023 compared with $7.7 million for the first quarter of 2022. The increase was primarily due to higher legal expenses resulting from a legal settlement in the first quarter.

 

The net loss for the first quarter of 2023 was $7.5 million, or $(0.28) per share, compared with net income of $5.6 million, or $0.32 per diluted share, for the prior-year quarter.

 

Adjusted EBITDA for the first quarter of 2023 was negative $4.0 million compared with negative $2.4 million for the first quarter of 2022, reflecting lower revenues in the 2023 quarter. Adjusted EBITDA, a non-GAAP financial measure, is defined as net income or loss excluding interest income and expense, income taxes, depreciation and amortization, and certain other non-recurring or non-cash items.

 

The below table presents a reconciliation from net income (loss) to Adjusted EBITDA for the first quarters of 2023 and 2022:

 

   Three Months Ended March 31,
   2023  2022
Net income (loss)  $(7,478)  $5,561 
Interest expense, net   35    33 
Income tax expenses   5    30 
Depreciation and amortization   266    131 
EBITDA   (7,172)   5,755 
           
Change in fair value of contingent consideration   (200)   

-

 
Change in fair value of warrant liabilities   (1,028)   (8,711)
Change in fair value of investments   2,941    

-

 
Legal settlement expenses   1,118    - 
Stock based compensation   351    517 
Adjusted EBITDA  $(3,990)  $(2,439)
Adjusted EBITDA margin   -45.7%   -25.0%

 

As of March 31, 2023, Biofrontera had cash and cash equivalents of $13.5 million compared with $17.2 million as of December 31, 2022. In addition, the Company had a $7.6 million investment in shares of Biofrontera AG as of March 31, 2023, and recently entered a $6.5 million secured line of credit. The Company believes its cash and cash equivalents are sufficient to fund operations for at least the next 12 months. Based on current operating plans and financial forecasts, we expect that our revolving line of credit and expected proceeds from the sale of our investment in Biofrontera AG in addition to our current cash and cash equivalents will be sufficient to fund our operations for at least the next twelve months from the date of issuance of our financial statements. However, we expect to have to obtain either equity or additional debt financing to support our future long-term growth and to mitigate the risk of our operating costs significantly exceeding the amounts currently estimated.

 

 

 

 

Financial Expectations

 

Biofrontera Inc. affirms its previously announced expectations for full-year 2023 growth in revenue to be at least 25% compared with 2022 and expects to be cash flow positive within approximately two years.

 

Conference Call and Webcast

 

Biofrontera Inc. will hold a conference call today at 8:30 a.m. Eastern time to discuss these results and answer questions.

 

  Date: Friday, May 12, 2023
  Time: 8:30 a.m. Eastern time
  Conference Call: 1-888-506-0062 (U.S. toll-free)
    1-973-528-0011 (international)
    Access Code: 104591
  Webcast: Live and 90-day replay webcast are available here and at investors.biofrontera-us.com.

 

About Biofrontera Inc.

 

Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatologic conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and Twitter.

 

Forward-Looking Statements

 

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the growth strategy for Biofrontera Inc.’s (the “Company”) 2023 revenue guidance, liquidity, proceeds from the sale of equity investments, clinical trials for Ameluz® and potential for label expansion, improved market opportunities, growth of the Company’s salesforce and its sales territories and the impact of expanding the Company’s salesforce on growth. We have based these forward-looking statements on our current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, including, but not limited to, the impact of any extraordinary external events; any changes in the Company’s relationship with its licensors; the ability of the Company’s licensors to fulfill their obligations to the Company in a timely manner; the Company’s ability to achieve and sustain profitability; whether the current global disruptions in supply chains will impact the Company’s ability to obtain and distribute its licensed products; changes in the practices of healthcare providers, including any changes to the coverage, reimbursement and pricing for procedures using the Company’s licensed products; the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz® in combination with BF-RhodoLED® in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; whether the market opportunity for Ameluz® in combination with BF-RhodoLED® is consistent with the Company’s expectations; the Company’s ability to comply with public company requirements; the Company’s ability to regain compliance with Nasdaq continued listing standards, the Company’s ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing and other factors that may be disclosed in the Company’s filings with the SEC, which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

 

Contact:

 

LHA Investor Relations

Tirth T. Patel

212-201-6614

tpatel@lhai.com

 

(Tables follow)

 

 

 

 

CONSOLIDATED BALANCE SHEETS

(In thousands, except par value and share amounts)

 

   March 31, 2023  December 31, 2022
   (Unaudited)   
ASSETS          
Current assets:          
Cash and cash equivalents  $13,505   $17,208 
Investment in equity securities   7,596    10,548 
Accounts receivable, net   4,116    3,748 
Other receivables, related party   3,750    3,658 
Inventories   6,670    7,168 
Prepaid expenses and other current assets   1,586    810 
           
Total current assets   37,223    43,140 
           
Other receivables long term, related party   -    2,813 
Property and equipment, net   197    204 
Operating lease right-of-use assets   1,234    1,375 
Intangible asset, net   2,927    3,032 
Other assets   384    320 
           
Total assets  $41,965   $50,884 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities:          
Accounts payable   887    1,278 
Accounts payable, related parties   912    1,312 
Acquisition contract liabilities, net   7,032    6,942 
Operating lease liabilities   484    498 
Accrued expenses and other current liabilities   11,135    10,864 
           
Total current liabilities   20,450    20,894 
           
Long-term liabilities:          
Acquisition contract liabilities, net   2,200    2,400 
Warrant liabilities   1,815    2,843 
Operating lease liabilities, non-current   725    848 
Other liabilities   24    21 
           
Total liabilities   25,214    27,006 
           
Stockholders’ equity:          
Preferred Stock, $0.001 par value, 20,000,000 shares authorized, zero shares issued and outstanding as of March 31, 2023 and December 31, 2022   -    - 
Common Stock, $0.001 par value, 300,000,000 shares authorized; 26,699,002 shares issued and outstanding as of March 31, 2023 and December 31, 2022   27    27 
Additional paid-in capital   103,721    103,370 
Accumulated deficit   (86,997)   (79,519)
           
Total stockholders’ equity   16,751    23,878 
           
Total liabilities and stockholders’ equity  $41,965   $50,884 

 

 

 

 

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts and number of shares)

(Unaudited)

 

   Three Months Ended March 31,
   2023  2022
       
Products revenues, net  $8,715   $9,736 
Revenues, related party   18    15 
           
Total revenues, net   8,733    9,751 
           
Operating expenses          
Cost of revenues, related party   4,547    4,975 
Cost of revenues, other   51    175 
Selling, general and administrative   9,800    7,616 
Selling, general and administrative, related party   27    95 
Change in fair value of contingent consideration   (200)   - 
           
Total operating expenses   14,225    12,861 
           
Loss from operations   (5,492)   (3,110)
           
Other income (expense)          
Change in fair value of warrant liabilities   1,028    8,711 
Change in fair value of investments   (2,941)   - 
Interest expense, net   (35)   (33)
Other income (expense), net   (33)   23 
           
Total other income (expense)   (1,981)   8,701 
           
Income (loss) before income taxes   (7,473)   5,591 
Income tax expense   5    30 
           
Net income (loss)  $(7,478)  $5,561 
           
Income (loss) per common share:          
Basic  $(0.28)  $0.33 
Diluted  $(0.28)  $0.32 
           
Weighted-average common shares outstanding:          
Basic   26,699,002    17,104,749 
Diluted   26,699,002    17,133,218 

 

# # #

 

 

 

 EX-99.2 3 ex99-2.htm

 

Exhibit 99.2

 

 

Biofrontera Inc. Announces Resignation of CEO

 

Executive Chairman Hermann Luebbert to Assume CEO Responsibilities, Reaffirms the Company’s Strategic Plan and 2023 Commercial Goals

 

WOBURN, Mass. (May 12, 2023) – Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces the resignation of Erica Monaco as Chief Executive Officer, which will be effective pending the completion of a near term transition of responsibilities with the Board of Directors. Hermann Luebbert, Biofrontera’s Executive Chairman and founder, will assume the CEO responsibilities. Ms. Monaco intends to pursue other professional opportunities and her resignation did not result from any disagreement with the Company on any matter, including any matter relating to its operations, policies or practices.

 

“Since founding Biofrontera in 1997, I have met few leaders like Erica who are capable of building a high-performance salesforce and carry out a commercial vision inspired by medical education. On behalf of the Biofrontera board of directors and my colleagues, I wish Erica all the best in her future endeavors. Biofrontera is fortunate to have a strong, capable team in place to continue driving our business forward without disruption. Our company’s strategic plan and our 2023 commercial goals remain unchanged,” said Mr. Luebbert.

 

“Tendering my resignation was a difficult, personal decision that I reached after much reflection. It has been a privilege to serve as Biofrontera’s CEO and to work closely with my inspiring colleagues,” said Ms. Monaco. “I am grateful for my time contributing to the growth and success of Biofrontera for the last seven years. I am proud of what our company and our people have accomplished as a team focused on bringing unparalleled therapies to the dermatology community. I wish my Biofrontera colleagues tremendous success and look forward to seeing them continue to grow and make an impact.”

 

About Biofrontera Inc.

 

Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatologic conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and Twitter.

 

 

 

 

Forward-Looking Statements

 

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the growth strategy for Biofrontera Inc.’s (the “Company”) strategic plan, 2023 commercial goals and potential for growth, and the transition of responsibilities at the Company. We have based these forward-looking statements on our current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, including, but not limited to, the impact of any extraordinary external events; any changes in the Company’s relationship with its licensors; the ability of the Company’s licensors to fulfill their obligations to the Company in a timely manner; the Company’s ability to achieve and sustain profitability; whether the current global disruptions in supply chains will impact the Company’s ability to obtain and distribute its licensed products; changes in the practices of healthcare providers, including any changes to the coverage, reimbursement and pricing for procedures using the Company’s licensed products; the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz® in combination with BF-RhodoLED® in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; whether the market opportunity for Ameluz® in combination with BF-RhodoLED® is consistent with the Company’s expectations; the Company’s ability to comply with public company requirements; the Company’s ability to regain compliance with Nasdaq continued listing standards, the Company’s ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing and other factors that may be disclosed in the Company’s filings with the SEC, which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

 

Contact:

 

LHA Investor Relations

Tirth T. Patel

212-201-6614

tpatel@lhai.com

 

# # #

 

 

 

 GRAPHIC 4 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end GRAPHIC 5 ex99-2_002.jpg begin 644 ex99-2_002.jpg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end EX-101.SCH 6 bfri-20230508.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 7 bfri-20230508_def.xml INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 bfri-20230508_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Class of Stock [Axis] Common stock, par value $0.001 per share Preferred Stock Purchase Rights Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $5.00 per share Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Information, Former Legal or Registered Name EX-101.PRE 9 bfri-20230508_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
May 08, 2023
Document Type 8-K
Amendment Flag false
Document Period End Date May 08, 2023
Entity File Number 001-40943
Entity Registrant Name Biofrontera Inc.
Entity Central Index Key 0001858685
Entity Tax Identification Number 47-3765675
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 120 Presidential Way
Entity Address, Address Line Two Suite 330
Entity Address, City or Town Woburn
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01801
City Area Code (781)
Local Phone Number 245-1325
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Entity Information, Former Legal or Registered Name Not Applicable
Common stock, par value $0.001 per share  
Title of 12(b) Security Common stock, par value $0.001 per share
Trading Symbol BFRI
Security Exchange Name NASDAQ
Preferred Stock Purchase Rights  
Title of 12(b) Security Preferred Stock Purchase Rights
Security Exchange Name NASDAQ
Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $5.00 per share  
Title of 12(b) Security Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $5.00 per share
Trading Symbol BFRIW
Security Exchange Name NASDAQ
XML 11 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001858685 2023-05-08 2023-05-08 0001858685 BFRI:CommonStockParValue0.001PerShareMember 2023-05-08 2023-05-08 0001858685 BFRI:PreferredStockPurchaseRightsMember 2023-05-08 2023-05-08 0001858685 BFRI:WarrantsEachWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf5.00PerShareMember 2023-05-08 2023-05-08 iso4217:USD shares iso4217:USD shares 0001858685 false 8-K 2023-05-08 Biofrontera Inc. DE 001-40943 47-3765675 120 Presidential Way Suite 330 Woburn MA 01801 (781) 245-1325 Not Applicable false false false false Common stock, par value $0.001 per share BFRI NASDAQ Preferred Stock Purchase Rights NASDAQ Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $5.00 per share BFRIW NASDAQ true false EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 4 25 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://biofrontera.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [dq-0546-SecurityExchangeName-TradingSymbol, NoTradingSymbolFlag-Dependency] In submission type 8-K, SecurityExchangeName may have a value if one of TradingSymbol, NoTradingSymbolFlag has a value in context From2023-05-082023-05-08_custom_PreferredStockPurchaseRightsMember. form8-k.htm 265 form8-k.htm bfri-20230508.xsd bfri-20230508_def.xml bfri-20230508_lab.xml bfri-20230508_pre.xml ex99-1.htm ex99-2.htm http://xbrl.sec.gov/dei/2022 true false JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 30 }, "contextCount": 4, "dts": { "definitionLink": { "local": [ "bfri-20230508_def.xml" ] }, "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "bfri-20230508_lab.xml" ] }, "presentationLink": { "local": [ "bfri-20230508_pre.xml" ] }, "schema": { "local": [ "bfri-20230508.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 67, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 25, "memberCustom": 3, "memberStandard": 0, "nsprefix": "BFRI", "nsuri": "http://biofrontera.com/20230508", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-05-08to2023-05-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://biofrontera.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-05-08to2023-05-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "BFRI_CommonStockParValue0.001PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock, par value $0.001 per share" } } }, "localname": "CommonStockParValue0.001PerShareMember", "nsuri": "http://biofrontera.com/20230508", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "domainItemType" }, "BFRI_PreferredStockPurchaseRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock Purchase Rights" } } }, "localname": "PreferredStockPurchaseRightsMember", "nsuri": "http://biofrontera.com/20230508", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "domainItemType" }, "BFRI_WarrantsEachWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf5.00PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $5.00 per share" } } }, "localname": "WarrantsEachWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf5.00PerShareMember", "nsuri": "http://biofrontera.com/20230508", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 19 0001493152-23-016502-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-016502-xbrl.zip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�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end